A new study published in the Journal of Alzheimer’s Disease has found that cannabis is not only an effective medicine in the early stages of dementia, it’s also effective in its late stages.
“Previous reports have demonstrated that the combination of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage”, begins the study’s abstract. “Here, we provide evidence that such natural cannabinoids are still effective in reducing memory impairment in AβPP/PS1 mice at advanced stages of the disease”.
The present study also demonstrates that natural cannabinoids “do not affect cognitive impairment associated with healthy aging in wild-type mice.”
The study concludes; “The positive effects induced by Δ9-THC and CBD in aged AβPP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Ra1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.”
The full study – titled Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Mode – can be found by clicking here.